Jodi L. Connolly, Ph.D.

Patent Agent« back


EDUCATION
  • Ph.D., Department of Microbiology and Immunology, Vanderbilt University, 2001
  • B.S. with Honors in Biology, minor in Chemistry, Willamette University, 1996
BAR ADMISSIONS
  • U.S. Patent and Trademark Office, 2003 (Reg. No. 54,044)
YEAR JOINED FIRM

2007

Practice Areas:

Patents

Technologies:

Life Sciences & Biotechnology

PRACTICE AREA OVERVIEW

Dr. Connolly prepares and prosecutes U.S., international, and foreign patent applications. Dr. Connolly also performs prior art searches and assists in the preparation of patentability opinions.

TECHNICAL EXPERTISE

Dr. Connolly’s expertise includes many areas of biotechnology, including virology, immunology, vaccines, oncology, monoclonal antibodies, molecular biology, genetics, biochemistry, gene therapy, RNA interference, and antisense technology.

PRIOR PROFESSIONAL EXPERIENCE

Isis Pharmaceuticals, Inc.
Senior Patent Agent | 2003 – 2007
Responsibilities included managing patent portfolios in the field of antisense technology and preparing and prosecuting U.S. and international patent applications.

Fish and Richardson, P.C.
Patent Agent | 2003
Practice emphasized patent prosecution in biotechnology, including gene therapy, molecular biology, biochemistry, virology, immunology, and medical devices.

Heller Ehrman White and McAuliffe, LLP
Scientific Advisor/Patent Agent | 2002 – 2003
Practice emphasized patent prosecution in biotechnology, including gene therapy, molecular biology, biochemistry, virology, immunology, and medical devices.

The Scripps Research Institute
Research Associate | 2001 – 2002
Studies focused on the interaction of adenovirus with cellular factors involved in the host innate immune response in order to better design an adenoviral gene therapy vector.

Vanderbilt University Medical Center
Graduate Student and Postdoctoral Research Fellow | 1996 – 2001
Research focused on elucidating the mechanisms by which double-stranded RNA viruses induce cell death and identifying viral and cellular components that result in viral pathogenesis in host organisms.

PROFESSIONAL ACTIVITIES
  • Member, American Intellectual Property Law Association
REPRESENTATIVE PATENTS
PRESENTATIONS AND PUBLICATIONS
  • S.E. Rodgers, J.L. Connolly, J.D. Chappell, and T.S. Dermody. 1998. Reovirus growth in cell culture does not require the full complement of viral proteins: Identification of a sls-null mutant. J. Virol. 72:8597-8604.
  • J.L. Connolly, S.E. Rodgers, P. Clarke, D.W. Ballard, L.D. Kerr, K.L. Tyler, and T.S. Dermody. 2000. Reovirus-induced apoptosis requires activation of transcription factor NF-kB. J. Virol. 74:2981-2989.
  • G.J. Poggioli, C.J. Keefer, J.L. Connolly, T.S. Dermody, and K.L. Tyler. 2000. Reovirus-induced G2/M cell cycle arrest requires s1s and occurs in the absence of apoptosis. J. Virol. 74:9562-9570.
  • E.S. Barton, J.L. Connolly, J.C. Forrest, and T.S. Dermody. 2001. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multi-step adhesion strengthening. J. Biol. Chem. 276:2200-2211.
  • E.S. Barton, J.C. Forrest, J.L. Connolly, J.D. Chappell, F.J. Schnell, A. Nusrat, C.A. Parkos, and T.S. Dermody. 2001. Identification of junction adhesion molecule as a reovirus receptor. Cell 104:441-451.
  • J.L. Connolly, E.S. Barton, and T.S. Dermody. 2001 Reovirus binding to cell-surface sialic potentiates virus-induced apoptosis. J. Virol. 75:4029-4039.
  • E.S. Barton, J.D. Chappell, J.L. Connolly, J.C. Forrest, and T.S. Dermody. 2001. Reovirus receptors and apoptosis. Virology 190:173-180.
  • J.L Connolly and T.S. Dermody. 2002. Virion Disassembly is Required for Reovirus-Induced Apoptosis. J. Virol. 76:1632-1641.
  • M. Filippova, H. Song, J.L. Connolly, Terence S. Dermody, and P.J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to TNF R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739
  • E.S. Barton, B.E. Youree, D.H. Ebert, J.C. Forrest, J.L. Connolly, T. Valyi-Nagy, K. Washington, J.D. Wetzel, and T.S. Dermody. 2003. Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease. J. Clin. Invest. 111:1823-1833
  • S.M. O’Donnell, M.W. Hansberger, J.L. Connolly, J.D. Chappell, M.J. Watson, J.M. Pierce, J.D. Wetzel, W. Han, E.S. Barton, J.C. Forrest, T. Valyi-Nagy, F.E. Yull, T.S. Blackwell, J.N. Rottman, B. Sherry and T.S. Dermody. 2005. Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease. J. Clin. Invest. 115:2341-2350
  • M. Iacobelli-Martinez, R.R. Nepomuceno, J. Connolly, G.R. Nemerow. CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines, 2005 J. Virol. 79:11259-68.